Skip to main content

Table 4 Percentage of responders in the clinical evaluation of cefditoren efficacy in clinical trials. Published data

From: Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults

 

References

Cefditoren 200 mg bid

Cefditoren 400 mg bid

Comparatorsa

EOTb

EFc

EOTb

EFc

EOTb

EFc

Pharyngotonsillitis

90-92

93.4 – 98.6

88.9–99.2

–

–

88.6–97.1

84.4–100

Rhinosinusitis

90,93

81.3–95.2

63.6–91.0

76.5–83.1

70.2–71.9

75.5–97.7

66.2–95.1

AECBd

89,94–97

80–88.8

79.7–83.0

84.4–95.5

78.1–85.6

75.0–98.9

79.8–85.7

CAPe

89,98,99

87.2 – 91.8

88.4–87.8

89.2–90.1

83.7–87.2

90.3–92.2

87.8–93.8

  1. aPenicillin V or VK (90–92) for pharyngotonsillitis, amoxicillin/clavulanic acid (90,93) or cefuroxime (90) for rhinosinusitis, cefuroxime (89,94,96) or clarithromycin (89,95) for AECB, and amoxicillin/clavulanic acid (89,98), and cefpodoxime (89,99) for CAP
  2. bEOT = End of Treatment
  3. cEF = End of Follow up
  4. dAECB = Acute exacerbation of chronic bronchitis
  5. eCAP = Community-acquired pneumonia